Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01536938 · ClinicalTrials.gov registry record · Phase 2
LEO 90100 in the Treatment of Psoriasis Vulgaris
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 303
- Enrollment target
NCT01536938: Completed Phase 2 study, sponsored by LEO Pharma.
NCT01536938 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 303 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (128% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01536938, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 303 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.
Primary Outcome
Assessment of disease severity (Plaque thickening, Scaling and Erythema) using a 5-point scale (Clear, Almost clear, Mild, Moderate, Severe), based on the condition of the disease at the time of evaluation.
Interventions
- DRUG LEO 90100
- DRUG Betamethasone
- DRUG Calcipotriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
What the finished NCT01536938 record still lists
NCT01536938 is an interventional study that assigns participants to a tested intervention. The registered 303 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (128% higher).
The record links to 0 conditions, and to 3 interventions - of which LEO 90100 is the first listed.
NCT01536938 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01536938 about?
NCT01536938 is a clinical study titled "LEO 90100 in the Treatment of Psoriasis Vulgaris". The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.
What is the current status of trial NCT01536938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2012-05. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01536938?
The interventions under investigation include: LEO 90100 (DRUG), Betamethasone (DRUG), Calcipotriol (DRUG).
Who is sponsoring clinical trial NCT01536938?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01536938's enrollment target sits among peer trials
303 167th of 2000 higher than 1,834 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia